Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Page 1
Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.
Wenzel HHB, Olthof EP, Bekkers RLM, Boere IA, Lemmens VEPP, Nijman HW, Stalpers LJA, van der Aa MA, van der Velden J, Mom CH. Wenzel HHB, et al. Among authors: nijman hw. Cancer Treat Rev. 2022 Jan;102:102311. doi: 10.1016/j.ctrv.2021.102311. Epub 2021 Nov 2. Cancer Treat Rev. 2022. PMID: 34773774 Free article. Review.
Additionally, both strategies are associated with varying types of adverse events, and affect quality of life and sexual functioning differently, both in the short and long term. Although total proportions of adverse events were comparable between treatment strategies, low …
Additionally, both strategies are associated with varying types of adverse events, and affect quality of life and sexual functioning differe …
Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making.
Post CCB, Mens JWM, Haverkort MAD, Koppe F, Jürgenliemk-Schulz IM, Snyers A, Roeloffzen EMA, Schaake EE, Slot A, Stam TC, Beukema JC, van den Berg HA, Lutgens LCHW, Nijman HW, de Kroon CD, Kroep JR, Stiggelbout AM, Creutzberg CL. Post CCB, et al. Among authors: nijman hw. Gynecol Oncol. 2021 Jun;161(3):727-733. doi: 10.1016/j.ygyno.2021.03.004. Epub 2021 Mar 10. Gynecol Oncol. 2021. PMID: 33712276 Free article.
Both patients and clinicians rated survival benefit most important during decision making, followed by long-term symptoms. Older patients (OR 0.92 [95%CI 0.87-0.97]; p = 0.003) with comorbidity (OR 0.34 [95% CI 0.12-0.89]; p = 0.035) had lower preference for chemoradiother …
Both patients and clinicians rated survival benefit most important during decision making, followed by long-term symptoms. Older pati …
Validation of the Dutch Version of the Brief Negative Symptom Scale.
Seelen-de Lang BL, Boumans CE, Nijman HLI. Seelen-de Lang BL, et al. Among authors: nijman hli. Neuropsychiatr Dis Treat. 2020 Oct 29;16:2563-2567. doi: 10.2147/NDT.S269037. eCollection 2020. Neuropsychiatr Dis Treat. 2020. PMID: 33154643 Free PMC article.
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.
Post CCB, de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger NPB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Kitchener HC, Nijman HW, Lutgens LCHW, Brooks S, Jürgenliemk-Schulz IM, Feeney A, Goss G, Fossati R, Ghatage P, Leary A, Do V, Lissoni AA, McCormack M, Nout RA, Verhoeven-Adema KW, Smit VTHBM, Putter H, Creutzberg CL. Post CCB, et al. Among authors: nijman hw. Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):975-986. doi: 10.1016/j.ijrobp.2020.10.030. Epub 2020 Oct 28. Int J Radiat Oncol Biol Phys. 2021. PMID: 33129910 Free article. Clinical Trial.
PURPOSE: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiation therapy versus pelvic radiation therapy alone. The present analysis was performed to compare long-term adverse events (AE) and …
PURPOSE: The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemorad …
Diagnose, indicate, and treat severe mental illness (DITSMI) as appropriate care: A three-year follow-up study in long-term residential psychiatric patients on the effects of re-diagnosis on medication prescription, patient functioning, and hospital bed utilization.
Veereschild HM, Noorthoorn EO, Nijman HLI, Mulder CL, Dankers M, Van der Veen JA, Loonen AJM, Hutschemaekers GJM. Veereschild HM, et al. Among authors: nijman hli. Eur Psychiatry. 2020 May 8;63(1):e47. doi: 10.1192/j.eurpsy.2020.46. Eur Psychiatry. 2020. PMID: 32381136 Free PMC article.
BACKGROUND: While polypharmacy is common in long-term residential psychiatric patients, prescription combinations may, from an evidence-based perspective, be irrational. ...CONCLUSIONS: Our results suggest that DITSMI can be recommended as an appropriate care for all long- …
BACKGROUND: While polypharmacy is common in long-term residential psychiatric patients, prescription combinations may, from an eviden …
Short-term surgical complications after radical hysterectomy-A nationwide cohort study.
Wenzel HHB, Kruitwagen RFPM, Nijman HW, Bekkers RLM, van Gorp T, de Kroon CD, van Lonkhuijzen LRCW, Massuger LFAG, Smolders RGV, van Trommel NE, Yigit R, Zweemer RP, van der Aa MA. Wenzel HHB, et al. Among authors: nijman hw. Acta Obstet Gynecol Scand. 2020 Jul;99(7):925-932. doi: 10.1111/aogs.13812. Epub 2020 Feb 6. Acta Obstet Gynecol Scand. 2020. PMID: 31955408 Free article.
This nationwide cohort study was conducted to determine the rate of short-term surgical complications and to evaluate its possible predictors in women with early-stage cervical cancer. ...Open surgery (OR 36.65; 95% CI 7.10-189.12) and body mass index (OR 1.15; 95% CI 1.08 …
This nationwide cohort study was conducted to determine the rate of short-term surgical complications and to evaluate its possible pr …
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group. de Boer SM, et al. Among authors: nijman hw. Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345626 Free PMC article. Clinical Trial.
This treatment schedule should be discussed and recommended, especially for women with stage III or serous cancers, or both, as part of shared decision making between doctors and patients. Follow-up is ongoing to evaluate long-term survival. FUNDING: Dutch Cancer Society, …
This treatment schedule should be discussed and recommended, especially for women with stage III or serous cancers, or both, as part of shar …
Screening for intellectual disabilities and borderline intelligence in Dutch outpatients with severe mental illness.
Seelen-de Lang BL, Smits HJH, Penterman BJM, Noorthoorn EO, Nieuwenhuis JG, Nijman HLI. Seelen-de Lang BL, et al. Among authors: nijman hli. J Appl Res Intellect Disabil. 2019 Sep;32(5):1096-1102. doi: 10.1111/jar.12599. Epub 2019 Apr 29. J Appl Res Intellect Disabil. 2019. PMID: 31033102
The prevalence of mild or borderline intellectual disabilities (MBID); an umbrella term for people with borderline intellectual functioning (BIF) and mild intellectual disability (MID) in this population is also unknown. ...
The prevalence of mild or borderline intellectual disabilities (MBID); an umbrella term for people with borderline intellectual funct …
Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG, Creutzberg CL, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LCHW, van der Steen-Banasik EM, Mens JWM, Slot A, Kroese MCS, van Triest B, Nijman HW, Stelloo E, Bosse T, de Boer SM, van Putten WLJ, Smit VTHBM, Nout RA; PORTEC Study Group. Wortman BG, et al. Among authors: nijman hw. Br J Cancer. 2018 Oct;119(9):1067-1074. doi: 10.1038/s41416-018-0310-8. Epub 2018 Oct 25. Br J Cancer. 2018. PMID: 30356126 Free PMC article. Clinical Trial.
BACKGROUND: PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT) with vaginal brachytherapy (VBT). We evaluated long-term outcomes combined with the results of pathology review an …
BACKGROUND: PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam r …
Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens.
van de Wall S, Ljungberg K, Ip PP, Boerma A, Knudsen ML, Nijman HW, Liljeström P, Daemen T. van de Wall S, et al. Among authors: nijman hw. Oncoimmunology. 2018 Jul 26;7(10):e1487913. doi: 10.1080/2162402X.2018.1487913. eCollection 2018. Oncoimmunology. 2018. PMID: 30288352 Free PMC article.
In addition, inclusion of a helper cassette and an ER targeting signal (sigHelp) did not significantly further enhance the suppression of tumor outgrowth in the long term, albeit exhibiting better tumor control early after immunization. ...
In addition, inclusion of a helper cassette and an ER targeting signal (sigHelp) did not significantly further enhance the suppression of tu …
27 results